Tel Aviv - Delayed Quote ILA

Teva Pharmaceutical Industries Limited (TEVA.TA)

Compare
6,400.00
-385.00
(-5.67%)
At close: January 30 at 5:24:47 PM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
16,772,000.00
15,845,000.00
14,925,000.00
15,879,000.00
16,658,000.00
Cost of Revenue
8,413,000.00
8,200,000.00
7,952,000.00
8,284,000.00
8,933,000.00
Gross Profit
8,358,000.00
7,645,000.00
6,973,000.00
7,594,000.00
7,726,000.00
Operating Expense
4,630,000.00
4,451,000.00
4,283,000.00
4,495,000.00
4,668,000.00
Operating Income
3,728,000.00
3,194,000.00
2,690,000.00
3,099,000.00
3,058,000.00
Net Non Operating Interest Income Expense
-1,050,000.00
-1,095,000.00
-991,000.00
-962,000.00
-963,000.00
Other Income Expense
-3,208,000.00
-2,723,000.00
-4,859,000.00
-1,480,000.00
-6,500,000.00
Pretax Income
-530,000.00
-624,000.00
-3,163,000.00
658,000.00
-4,406,000.00
Tax Provision
689,000.00
-7,000.00
-643,000.00
211,000.00
-168,000.00
Earnings from Equity Interest Net of Tax
2,000.00
2,000.00
21,000.00
9,000.00
138,000.00
Net Income Common Stockholders
-959,000.00
-559,000.00
-2,446,000.00
417,000.00
-3,990,000.00
Diluted NI Available to Com Stockholders
-959,000.00
-559,000.00
-2,446,000.00
417,000.00
-3,990,000.00
Basic EPS
-0.85
-0.50
-2.12
0.38
-3.64
Diluted EPS
-0.85
-0.50
-2.12
0.38
-3.64
Basic Average Shares
1,127,250.00
1,119,000.00
1,110,000.00
1,102,000.00
1,095,000.00
Diluted Average Shares
1,127,250.00
1,119,000.00
1,110,000.00
1,107,000.00
1,095,000.00
Total Operating Income as Reported
482,000.00
433,000.00
-2,197,000.00
1,716,000.00
-3,572,000.00
Total Expenses
13,043,000.00
12,651,000.00
12,235,000.00
12,779,000.00
13,601,000.00
Net Income from Continuing & Discontinued Operation
-959,000.00
-559,000.00
-2,446,000.00
417,000.00
-3,990,000.00
Normalized Income
1,512,700.00
2,122,910.00
1,420,400.00
1,409,503.04
1,427,664.00
Interest Expense
984,000.00
1,029,000.00
930,000.00
891,000.00
901,000.00
Net Interest Income
-1,050,000.00
-1,095,000.00
-991,000.00
-962,000.00
-963,000.00
EBIT
454,000.00
405,000.00
-2,233,000.00
1,549,000.00
-3,505,000.00
EBITDA
1,510,000.00
1,558,000.00
-925,000.00
2,879,000.00
-1,948,000.00
Reconciled Cost of Revenue
8,413,000.00
8,200,000.00
7,952,000.00
8,284,000.00
8,933,000.00
Reconciled Depreciation
1,056,000.00
1,153,000.00
1,308,000.00
1,330,000.00
1,557,000.00
Net Income from Continuing Operation Net Minority Interest
-959,000.00
-559,000.00
-2,446,000.00
417,000.00
-3,990,000.00
Total Unusual Items Excluding Goodwill
-3,210,000.00
-2,709,000.00
-4,833,000.00
-1,461,000.00
-6,496,000.00
Total Unusual Items
-3,210,000.00
-2,709,000.00
-4,833,000.00
-1,461,000.00
-6,496,000.00
Normalized EBITDA
4,720,000.00
4,267,000.00
3,908,000.00
4,340,000.00
4,548,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-738,300.00
-27,090.00
-966,600.00
-468,496.96
-1,078,336.00
12/31/2020 - 8/12/2002

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ALVO Alvotech
12.41
-1.27%
 
KMDA.TA Kamada Ltd.
2,435.00
-0.86%
 
KMDA Kamada Ltd.
6.71
-0.45%
 
SFZN.SW Siegfried Holding AG
1,024.00
+1.19%
 
PRGO Perrigo Company plc
24.93
+1.05%
 
INCR InterCure Ltd.
1.6699
-0.60%
 
CANN Trees Corporation
0.0260
-21.21%
 
RDHL RedHill Biopharma Ltd.
5.93
-2.15%
 
SDZ.SW Sandoz Group AG
43.35
+1.67%
 
AX9.SG Akebia Therapeutics Inc
2.2000
+0.73%